CoLucid Pharmaceuticals Grabs $37M for Phase 3 Trials
January 14, 2015
CoLucid Pharmaceuticals is developing treatments for CNS disorders. Its $37.1 million Series C financing will go toward the Phase 3 trial program for its oral lasmiditan, which is designed to deliver headache relief without potential liabilities of vasoconstriction. In 2011, CoLucid raised a $7.5 million Series B round that valued it at $76 million.